IFRX: InflaRx NV Price to Sales
The battle for inclusion in government treatment protocols among biotech giants creates intense competition. The price-to-sales multiple demonstrates the asset's dynamics, where 386.20 captures the value of this parameter. Sufficient reserves and government procurement of respiratory syndrome treatments ensure stability. Clinical phase risks are mitigated through the diversification of R&D in oncology and immunology for InflaRx N.V. (IFRX).
Metric breakdowns and analytics for InflaRx N.V. (IFRX)
- stock price and consensus target price:
- market capitalization information:
- shareholders' equity book value data:
- debt obligations and liquidity statistics:
- net income and valuation ratios data:
IFRX - Net Income|Expected Net Income InflaRx N.V.|IFRX - Price to Earnings Ratio|Price to Future Earnings Ratio inflarx.de|IFRX - Price/Earnings to Growth Multiple|Total Company Value to Operating Income Before Depreciation Ratio InflaRx GmbH|IFRX - Operating profit before deduction of amortization|Earnings per share for the last twelve months InflaRx|IFRX - Net earnings per share for the last 12 months|Year-over-year net earnings per share change for the last twelve months inflarx.de|IFRX - Earnings growth in current year|Consensus forecast of earnings per share growth for next year InflaRx N.V.
- total revenue and sales volume data:
General company analysis:IFRX InflaRx NV
Investors are evaluating the potential of InflaRx N.V. (IFRX) through the lens of its technological solutions' scalability. The P/S ratio determines the market value of one unit of annual revenue, allowing for an assessment of the premium paid for future business growth. By analyzing the P/S ratio chart on GURU.Markets, one can compare market capitalization with the efficiency of implementing robotic biomaterial analysis systems. This metric helps determine whether the company's valuation is fair during the automation phase of laboratory processes.
Competitors of InflaRx N.V.
argenx.com - Market Cap to Revenue Ratio|P/S Multiple BNTX (BioNTech)|Abivax Pharma (ABVX) - Price to Sales|ADMA Bio - P/S Multiple|Price-to-Revenue Coefficient Protagonist Corp PTGX|Immunovant, Inc. (IMVT) - Price-to-Revenue Ratio|Market Cap to Revenue Ratio KNSA|GRFS (Grifols) - P/S Multiple|Adaptive Biotech - Price-to-Sales Ratio|Price-to-Revenue Ratio Celldex (CLDX)|Price-to-Revenue Ratio AUPH (Aurinia Corp)|P/S Multiple BCRX (BioCryst)|P/S Multiple veratx.com VERA|DNTH - Price-to-Revenue Ratio|Market Capitalization-to-Revenue Ratio PHVS (Pharvaris NV)|ABCL (AbCellera Biologics Inc) - Market Cap to Revenue|Market Cap to Revenue Ratio TRML|Market Cap to Revenue PGEN|PHAR: Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio Nektar Therapeutics Inc. (NKTR)|Upstream Bio, Inc. - Market Cap to Revenue Ratio|Zenas Biopharma, Inc. - Market Cap to Revenue|Price-to-Revenue Coefficient Immunome Bio (IMNM)|GOSS: Market Cap to Revenue|KALV: Price-to-Revenue Ratio|SEPN (Septerna) - Market Cap to Revenue|PVLA - Price-to-Revenue Coefficient|SVRA (Savara Corp) - P/S Multiple|Rigel Corp (RIGL) - Price-to-Revenue Coefficient|P/S Multiple ANAB|ATXS: Price-to-Sales Ratio|Price-to-Revenue Ratio enGene ENGN|Market Capitalization-to-Revenue Ratio RAPT|JBIO: Market Cap to Revenue|ACRS (Aclaris Therapeutics, Inc) - Market Cap to Revenue Ratio|Kyverna Therapeutics (KYTX) - Price-to-Revenue Ratio|Price-to-Sales Ratio TLSA (tizianalifesciences.com)|CABA (Cabaletta Bio) - P/S Multiple|VTYX: Market Capitalization-to-Revenue Ratio|P/S Multiple THTX|P/S Multiple Avalo Therapeutics Inc (AVTX)|Price-to-Revenue Ratio Eledon Pharmaceuticals ELDN|Market Capitalization-to-Revenue Ratio AGEN|CLYM - Price-to-Revenue Ratio|Zura Bio Ltd (ZURA) - Market Cap to Revenue|ATYR: P/S Multiple|Adagene Inc. (ADAG) - P/S Multiple|Market Cap to Revenue IMA|STTK: Market Capitalization-to-Revenue Ratio|P/S Multiple EQ|Price-to-Revenue Coefficient connectbiopharm.com|Price-to-Revenue Ratio Immunic IMUX|ATRA - Market Cap to Revenue|XFOR - Price-to-Revenue Ratio|Adicet Bio (ACET) - Market Cap to Revenue|CELU (celularity.com) - Market Cap to Revenue|INmune Bio Inc (INMB) - P/S Multiple|Price-to-Revenue Ratio Barinthus Bio|Market Cap to Revenue Ratio KZR (Kezar Life Sciences Inc)|P/S Multiple SABS|AKTX - Price to Sales|P/S Multiple ENLV (Enlivex Therapeutics Ltd.)|Price-to-Revenue Coefficient Q32 Bio Inc (QTTB)|GOVX - Price-to-Revenue Ratio|EDSA (Edesa Biotech Corp) - Market Cap to Revenue Ratio|IBIO: P/S Multiple|Price-to-Sales Ratio CARM (Carisma Therapeutics Inc.)|Price-to-Revenue Ratio XTL Biopharmaceuticals Ltd.|Price-to-Revenue Ratio BOLT|P/S Multiple HCWB|P/S Multiple aptevotherapeutics.com (APVO)|Price-to-Revenue Ratio AIM ImmunoTech Inc. AIM|Market Capitalization-to-Revenue Ratio ADTX|GRI: Market Cap to Revenue|XRTX (XORTX Therapeutics Inc) - Market Cap to Revenue Ratio|HIND (ReShape Lifesciences) - Market Cap to Revenue|Revelation Biosciences Corp - Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio Indaptus Therapeutics|Market Cap to Revenue Ratio SCNI (scinai.com)|Market Cap to Revenue CALI (CalciMedica, Inc.)|Price-to-Revenue Coefficient affimed.com|Allakos - Market Cap to Revenue|HOOKIPA Pharma, Inc. - Price-to-Revenue Ratio|IGMS: Market Cap to Revenue|Price-to-Revenue Coefficient iteostherapeutics.com ITOS|OCEA: P/S Multiple|TCBP - Price-to-Revenue Coefficient|THRD (Third Harmonic Bio, Inc) - P/S Multiple
